• 1
    Edwards BK,Brown ML,Wingo PA, et al. Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst. 2005; 97: 14071427.
  • 2
    Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res. 2003; 284: 122130.
  • 3
    Fukuoka M,Yano S,Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol. 2003; 21: 22372246.
  • 4
    Kris MG,Natale RB,Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 2003; 290: 21492158.
  • 5
    Perez-Soler R,Chachoua A,Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004; 22: 32383247.
  • 6
    Kris MG,Sandler A,Miller VA, et al. Cigarette smoking history predicts sensitivity to erlotinib: results of a phase II trial in patients with bronchioloalevolar carcinoma. J Clin Oncol. 2004; 22: 631s.
  • 7
    Miller VA,Kris MG,Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol. 2004; 22: 11031109.
  • 8
    Lynch TJ,Bell DW,Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 21292139.
  • 9
    Paez JG,Janne PA,Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 14971500.
  • 10
    Cappuzzo F,Hirsch FR,Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005; 97: 643655.
  • 11
    Gazdar AF,Shigematsu H,Herz J,Minna JD. Mutations and addiction to EGFR: the Achilles ‘heal’ of lung cancers? Trends Mol Med. 2004; 10: 481486.
  • 12
    Lippman SM,Gibson N,Subbaramaiah K,Dannenberg AJ. Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clin Cancer Res. 2005; 11: 60976099.
  • 13
    Smith WL,DeWitt DL,Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem. 2000; 69: 145182.
  • 14
    DeWitt DL. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biophys Acta. 1991; 1083: 121134.
  • 15
    Subbaramaiah K,Telang N,Ramonetti JT, et al. Transcription of cyclooxygenase-2 is enhanced in transformed mammary epithelial cells. Cancer Res. 1996; 56: 44244429.
  • 16
    Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (pt II). J Natl Cancer Inst. 1998; 90: 16091620.
  • 17
    Goodwin JS,Ceuppens J. Regulation of the immune response by prostaglandins. J Clin Immunol. 1983; 3: 295315.
  • 18
    Sheng H,Shao J,Morrow JD,Beauchamp RD,DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998; 58: 362366.
  • 19
    Sheng H,Shao J,Washington MK,DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem. 2001; 276: 1807518081.
  • 20
    Tsujii M,Kawano S,Tsuji S,Sawaoka H,Hori M,DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998; 93: 705716.
  • 21
    Hida T,Yatabe Y,Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res. 1998; 58: 37613764.
  • 22
    Hida T,Kozaki K,Muramatsu H, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res. 2000; 6: 20062011.
  • 23
    Wolff H,Saukkonen K,Anttila S,Karjalainen A,Vainio H,Ristimaki A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res. 1998; 58: 49975001.
  • 24
    Buchanan FG,Wang D,Bargiacchi F,DuBois RN. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003; 278: 3545135457.
  • 25
    Dannenberg AJ,Subbaramaiah K. Targeting cyclooxygenase-2 in human neoplasia: rationale and promise. Cancer Cell. 2003; 4: 431436.
  • 26
    Pai R,Soreghan B,Szabo IL,Pavelka M,Baatar D,Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002; 8: 289293.
  • 27
    Dohadwala M,Yang SC,Luo J, et al. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. Cancer Res. 2006; 66: 53385345.
  • 28
    Griffin G,Thelemann A,McCormack S, et al. Characterization of the molecular determinants of erlotinib sensitivity in NSCLC cell lines. Proc Am Assoc Cancer Res. 2005; 46: 543. Abstract 2313.
  • 29
    Torrance CJ,Jackson PE,Montgomery E, et al. Combinatorial chemoprevention of intestinal neoplasia. Nat Med. 2000; 6: 10241028.
  • 30
    Gadgeel S,Ruckdeschel JC,Heath EI, et al. Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). J Thorac Oncol. 2007; 2: 299305.
  • 31
    Dowlati A,Nethery D,Kern JA. Combined inhibition of epidermal growth factor receptor and JAK/STAT pathways results in greater growth inhibition in vitro than single agent therapy. Mol Cancer Ther. 2004; 3: 459463.
  • 32
    Shepherd FA,Rodrigues PJ,Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353: 123132.
  • 33
    Sordella R,Bell DW,Haber DA,Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004; 305: 11631167.
  • 34
    Paz-Ares L,Sanchez J,Garcia-Velasco A, et al. A prospective phase II trial of erlotinib in advanced non-small cell lung cancer patients with mutations in the tyrosine kinase domain of the epidermal growth factor receptor. J Clin Oncol. 2006; 24: 18S. Abstract 7020.
  • 35
    Peyton M,Girard L,Shigematsu H, et al. Gefitinib and erlotinib sensitivity in a panel of non-small cell lung cancer (NSCLC) cell lines. Proc Am Assoc Cancer Res. 2005; 46: 799. Abstract 3389.
  • 36
    Reckamp KL,Krysan K,Morrow JD, et al. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res. 2006; 12: 33813388.
  • 37
    Janne PA,Johnson BE. Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res. 2006; 12: 4416s20s.